Orally active purine-based inhibitors of the heat shock protein 90

Journal of Medicinal Chemistry

Volumn 49, Issue 2, 2006, Pages 817-828

  Biamonte, Marco A ^a,b   Shi, Jiandong ^a,b   Hong, Kevin ^a,b   Hurst, David C ^a,b   Zhang, Lin ^a,b   Fan, Junhua ^a,b   Busch, David J ^a,b   Karjian, Patricia L ^a,b   Maldonado, Angelica A ^a,b   Sensintaffar, John L ^a,b   Yang, Yong Ching ^a,b   Kamal, Adeela ^a,b   Lough, Rachel E ^a,b   Lundgren, Karen ^a,b   Burrows, Francis J ^a,b   Timony, Gregg A ^a,b   Boehm, Marcus F ^a,b   Kasibhatla, Srinivas R ^a,b  

^a BIOGEN   (United States)

^b Department of Medicinal Chemistry ^*

Author keywords

[No Author keywords available]

Indexed keywords

8 (2 IODO 5 METHOXYPHENYLSULFANYL) 9 (3 ISOPROPYLAMINOPROPYL) 9H PURIN 6 YLAMINE; 9 (3 SEC BUTYLAMINOPROPYL) 8 (2 IODO 5 METHOXYPHENYLSULFANYL) 9H PURIN 6 YLAMINE; 9 [2 (2,2 DIMETHYLPROPYLAMINO)ETHYL] 8 (2 IODO 5 METHOXYPHENYLSULFANYL) 9H PURIN 6 YLAMINE; ADENINE DERIVATIVE; AMINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; IODINE DERIVATIVE; PHOSPHATE; PROTEIN INHIBITOR; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PROTEIN DEGRADATION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; HSP90 HEAT-SHOCK PROTEINS; MICE; MICE, NUDE; PURINES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 31544433450     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0503087     Document Type: Article

References (44)

1. For recent reviews, see: (a) Kamal, A.; Boehm, M. F.; Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 2004, 10, 283-290.
2. (b) Dymock, B. W.; Drysdale, M. J.; McDonald, E.; Workman, P. Inhibitors of Hsp90 and other chaperones for the treatment of cancer. Expert Opin. Ther. Pat. 2004, 14, 837-847.
3. (c) Isaacs, J. S.; Wanping, X.; Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3, 213.
4. (d) Maloney, A.; Workman, P. Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002, 2, 3-24
5. (e) Richter, K.; Buchner, J. Hsp90: Chaperoning signal transduction. J. Cell. Physiol. 2001, 188, 281-290.
6. For lists of client proteins; (a) Pratt, W. B.; Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based machinery. Exp. Biol. Med. 2003, 228, 111-133.
7. (b) Workman, P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004, 206, 149-157.
8. (c) Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 2004, 82, 488-499.
9. Gorre, M. E.; Ellwood-Yen, K.; Chiosis, G.; Rosen, N.; Sawyers, C. L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002, 100, 3041-3044.
10. (a) Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410.
11. (b) Workman, P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 2004, 10, 47-51.
12. Yun, B.-G.; Huang, W.; Leach, N.; Hartson, S. D.; Matts, R. L. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 2004, 43, 8217-8229.
13. The NCI clinical protocol consists of injecting a DMSO solution of 17-AAG.
14. (a) Glaze, E. R.; Smith, A. C.; Johnson, D. W.; McCormick, D. L.; Brown, A. B.; Levin, B. S.; Krishnaraj, R.; Lyubimov, A.; Egorin, M. J.; Tomaszewski, J. E. Dose range-finding toxicity studies of 17-DMAG. Proc. Am. Assoc. Cancer. Res. 2003, 44, 162-162.
15. (b) Eiseman, J. L.; Lan, J.; Lagatutta, T. F.; Hamburger, D. R.; Joseph, E.; Covey, J. M.; Egorin, M. J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C. B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 2005, 55, 21-32.
16. (a) Ikuina, Y.; Amishiro, N.; Miyata, M.; Narumi, H.; Ogawa, H.; Akiyama, T.; Shiotsu, Y.; Akinaga, S.; Murakata, C. Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol. J. Med. Chem. 2003, 46, 2534-2541.
17. Furthermore, radicicol and its oximes contain an oxirane ring which has been viewed as a liability for stability and toxicity, prompting the synthesis of cycloproparadicicol: (b) Yang, Z. Q.; Geng, X.; Solit, D.; Pratilas, C. A.; Rosen, N.; Danishefsky, S. J. New efficient synthesis of resorcinylic macrolides via ynolides; establishment of cycloproparadicicol as synthetic feasible preclinical anticancer agent based on Hsp90 as the target. J. Am. Chem. Soc. 2004, 126, 7881.
18. (b) Yang, Z.-Q.; Danishefsky, S. J. A concise route to benzofused macrolactones via ynolides: cycloproparadicicol. J. Am. Chem. Soc. 2003, 125, 9602-9603.
19. (a) Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HER-2 tyrosine kinase. Bioorg. Med. Chem. Lett. 2002, 10, 3555-3564.
20. (b) Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen, N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 2004, 11, 787-797.
21. (c) Chiosis, G.; Rosen, N. Small molecule composition for binding to Hsp90. WO 0236075, 2002.
22. (a) Drysdale, M. J.; Dymock, B. W.; Barril-Alonso, X.; Workman, P. 3,4-Diarylpyrazoles and their use in the therapy of cancer. WO 03/055860 A1, 2003.
23. (b) Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, a.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms Chem. Biol. 2004, 11, 775-785.
24. (c) Dymock, B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 2004, 14, 325-328.
25. (d) Dymock, B. W.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Massey, A.; McDonald, E.; Hubbard, R. E.; Surgenor, A.; Roughley, S. D.; Webb, P.; Workman, P.; Wright, L.; Drysdale, M. J. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design J. Med. Chem. 2005, 48, 4212-4215. Structure of Hsp90 in complex with 3a: pdb code 1UY6, and with 3b: pdb code 1UYF.
26. Clevenger, R. D.; Blagg, B. S. J. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Org. Lett. 2004, 6, 4459-4462.
27. Chiosis, G.; Lucas, B.; Huezo, H.; Solit, D.; Basso, A.; Rosen, N. Development of purine-scaffold small molecule inhibitors of Hsp90, Curr. Cancer Drug Targets 2003, 3, 371-376.
28. The benzene ring of 3a was not designed to have exactly the same orientation as the quinone ring of geldanamycin. Rather, the trimethoxybenzene moiety was designed to point in the same general direction and form a hydrogen bond with Lys112, an amino acid which forms a hydrogen bond with the quinone ring of geldanamycin.
29. Kasibhatla, S. R.; Zhang, L.; Boehm, M. F.; Fan, J.; Hong, K.; Shi, J.; Biamonte, M. A. Purine Analogues Having Hsp90 Inhibiting Activity. WO 3037860, 2003.
30. Llauger, L.; He, H.; Kim, J.; Aguirre, J.; Rosen, N.; Peters, U.; Davies, P. Chiosis, G. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 2005, 48, 2892-2905.
31. The free base of 2,3,5,6-tetraaminopyrimidine, a key intermediate in the production of 2-fluoroadenines, could also be obtained from the commercial sulfate salt and was acylated in NMP by a similar process.
32. Janeba, Z.; Holy, A.; Masojidkova, M. Synthesis of acyclic nucleoside and nucleotide analogues derived from 6-amino-7H-purin-8(9H)-one. Collect. Czech. Chem. Commun. 2000, 65, 1126-1144.
33. (a) Ma, C.; Liu, X.; Li, X.; Flippen-Anderson, J.; Yu, S.; Cook, J. M. Efficient asymmetric synthesis of biologically important tryptophan analogues via a palladium-mediated heteroannulation reaction. J. Org. Chem. 2001, 66, 4525-4542.
34. (b) Flynn, B. L.; Verdier-Pinard, P.; Hamel, E. A. Novel palladium-mediated coupling approach to 2,3-disubstituted benzo[b]thiophenes and its application to the synthesis of tubulin binding agents. Org. Lett. 2001, 3, 651-654.
35. Biamonte, M. A.; Shi, J.; Hurst, D.; Hong, K.; Boehm, M. F.; Kasibhatla, S. R. Preparation of 8-(arylsulfanyl)adenines with diazonium salts under mild, aerobic conditions. J. Org. Chem. 2005, 70, 717-720.
36. Le Brazidec, J.-Y.; Kamal, A.; Busch, D.; Thao, L.; Zhang, L.; Timony, G.; Grecko, R.; Trent, K.; Lough, R.; Salazar, T.; Khan, S.; Burrows, F.; Boehm, M. F. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. J. Med. Chem. 2004, 47, 3865-3873.
37. Prepared in a manner analogous to 8 (Scheme 1, route A) but replacing BuI with other alkylating agents.
38. Purified soy-derived L-α-phosphatidylcholine (Phospholipon 90H) was purchased from American Lecithin Company.
39. Not every kinase inhibitor has a short-lasting effect. Some are irreversible inhibitors or have slow off-rate kinetics, while others can sequester the kinase into inactive turners, causing their internalization. For examples, see: (a) Tsou, H.-R.; Overbeek-Klumpers, E. G.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Nilakantan, R.; Discafanl, C.; Golas, J.; Rabindran, S. K.; Shen, R.; Shi, X.; Wang, Y.-F.; Upeslacis, J.; Wissner, A. Optimization of 6,7-disubstituted-4-(arylamino) quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 2005, 48, 1107-1131.
40. (b) Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Pennisi, C.; Horne, E.; Lackey, K.; Allgood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 15, 6652-6659.
41. (c) Lichtner, R. B.; Menrad, A.; Sommer, A.; Klar, U.; Schneider, M. R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 2001, 61, 5790-5795.
42. Childress, S. J.; McKee, R. L. Chloroaminopyrimidines. J. Am. Chem. Soc. 1950, 72, 4271-4272.
43. (a) Beaman, A. G.; Gerster, J. F.; Robins, R. K. Potential purine antagonists. XXVIII. The preparation of various bromopurines. J. Org. Chem. 1962, 27, 986-990.
44. (b) Holy, A.; Günter, J.; Dvorakova, H.; Masojidkova, M.; Andrei, G.; Snoeck, R.; Balzarini, J.; De Clercq, E. Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy) ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base. J. Med. Chem. 1999, 42, 2064-2086.